+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Interleukin"

Chronic Rhinosinusitis With Nasal Polyps - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Rhinosinusitis With Nasal Polyps - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Still's Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Still's Disease- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-2 (IL-2) Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-2 (IL-2) Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adult-Onset Still Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Adult-Onset Still Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Cryoprin-Associated Periodic Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Cryoprin-Associated Periodic Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Interleukin-10 (IL-10) Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-10 (IL-10) Receptor Agonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-12 (IL-12) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-12 (IL-12) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-17 (IL-17) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-17 (IL-17) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-5 (IL-5) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-5 (IL-5) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-8 (IL-8) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-8 (IL-8) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
From
From
From
From
ENSPRYNG Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

ENSPRYNG Emerging Drug Insight and Market Forecast - 2032

  • Report
  • March 2023
  • 30 Pages
  • Global
From
COSENTYX Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

COSENTYX Emerging Drug Insight and Market Forecast - 2032

  • Report
  • March 2023
  • 30 Pages
  • Global
From
STELARA Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

STELARA Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
Loading Indicator

Interleukins are a group of cytokines, or proteins, that are involved in the regulation of the immune system. They are produced by a variety of cells, including T cells, B cells, and macrophages, and are involved in a wide range of biological processes, including inflammation, cell growth, and differentiation. Genomics has enabled researchers to better understand the role of interleukins in the immune system, and to develop new therapies for a variety of diseases. In recent years, the interleukin market has grown significantly, with a number of companies developing new therapies and diagnostic tests. Companies such as AbbVie, Amgen, and Novartis are developing new interleukin-based therapies for a variety of diseases, while companies such as Genentech and Merck are developing diagnostic tests to detect interleukin levels in patients. Additionally, a number of biotechnology companies are developing new interleukin-based therapies for a variety of diseases. Show Less Read more